CL2014003051A1 - Anticuerpo de unión a hemaglutinina (ha) de diversos virus de la influenza; ácido nucleico que lo codifica; vector; célula huésped; método de elaboración; método de detección de virus de la influenza; composición farmacéutica; vacuna; y kit. - Google Patents

Anticuerpo de unión a hemaglutinina (ha) de diversos virus de la influenza; ácido nucleico que lo codifica; vector; célula huésped; método de elaboración; método de detección de virus de la influenza; composición farmacéutica; vacuna; y kit.

Info

Publication number
CL2014003051A1
CL2014003051A1 CL2014003051A CL2014003051A CL2014003051A1 CL 2014003051 A1 CL2014003051 A1 CL 2014003051A1 CL 2014003051 A CL2014003051 A CL 2014003051A CL 2014003051 A CL2014003051 A CL 2014003051A CL 2014003051 A1 CL2014003051 A1 CL 2014003051A1
Authority
CL
Chile
Prior art keywords
vaccine
kit
vector
nucleic acid
pharmaceutical composition
Prior art date
Application number
CL2014003051A
Other languages
English (en)
Spanish (es)
Inventor
Vidya Subramanian
Zachary Shriver
Karthik Viswanathan
Sasisekharan Raguram
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49548781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003051(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of CL2014003051A1 publication Critical patent/CL2014003051A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
CL2014003051A 2012-05-10 2014-11-10 Anticuerpo de unión a hemaglutinina (ha) de diversos virus de la influenza; ácido nucleico que lo codifica; vector; célula huésped; método de elaboración; método de detección de virus de la influenza; composición farmacéutica; vacuna; y kit. CL2014003051A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261645554P 2012-05-10 2012-05-10
US201261716447P 2012-10-19 2012-10-19
US13/830,367 US9969794B2 (en) 2012-05-10 2013-03-14 HA binding agents

Publications (1)

Publication Number Publication Date
CL2014003051A1 true CL2014003051A1 (es) 2015-07-10

Family

ID=49548781

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003051A CL2014003051A1 (es) 2012-05-10 2014-11-10 Anticuerpo de unión a hemaglutinina (ha) de diversos virus de la influenza; ácido nucleico que lo codifica; vector; célula huésped; método de elaboración; método de detección de virus de la influenza; composición farmacéutica; vacuna; y kit.

Country Status (13)

Country Link
US (5) US9969794B2 (enExample)
EP (2) EP3689377A1 (enExample)
JP (2) JP6363066B2 (enExample)
KR (2) KR102194936B1 (enExample)
CN (2) CN108948189A (enExample)
AU (3) AU2013259371B2 (enExample)
CA (1) CA2872308C (enExample)
CL (1) CL2014003051A1 (enExample)
ES (1) ES2785306T3 (enExample)
IL (1) IL235585B (enExample)
MX (2) MX366180B (enExample)
SG (2) SG11201407265RA (enExample)
WO (1) WO2013170139A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
CA2906676A1 (en) 2013-03-14 2014-09-25 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
EP2970397A2 (en) 2013-03-14 2016-01-20 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CA2975655C (en) 2015-02-05 2023-09-19 Janssen Vaccines & Prevention B.V. Binding molecules directed against influenza hemagglutinin and uses thereof
EP3280730B1 (en) * 2015-04-08 2024-01-03 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
CA2985402A1 (en) * 2015-05-11 2016-11-17 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing peptidomimetic compounds
AU2016270147B2 (en) * 2015-06-03 2018-08-23 Xiamen University Broad-spectrum monoclonal anti-flu B antibody and uses thereof
EP3374390A1 (en) * 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN109069628A (zh) * 2016-01-14 2018-12-21 Bps生物科学有限公司 抗pd-1抗体及其用途
CA3015347A1 (en) * 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
JP6800591B2 (ja) * 2016-03-11 2020-12-16 国立大学法人 岡山大学 インフルエンザ治療剤
WO2017192589A1 (en) * 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to influenza ha and their use and identification
JP7372925B2 (ja) 2018-01-26 2023-11-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド インフルエンザヘマグルチニンに対するヒト抗体
GB201814959D0 (en) * 2018-09-14 2018-10-31 Secr Defence Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses
GB2578163A (en) * 2018-10-19 2020-04-22 Univ Pretoria Plant produced avian influenza antigens and their uses in diagnostic assays and devices
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
JP2023506156A (ja) * 2019-12-11 2023-02-15 ビステラ， インコーポレイテッド インフルエンザを処置または予防するための組成物および方法
EP4441091A4 (en) * 2021-11-30 2025-12-17 Sab Llc UNGULATE-DERIVED POLYCLONAL IMMUNE GLOBULIN SPECIFIC FOR INFLUENCE VAVIRUS AND USES THEREOF

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL23522C (enExample) 1927-03-23
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
FI83662C (fi) 1980-07-17 1991-08-12 Scripps Clinic Res Diagnostik antikropp och foerfarande foer dess framstaellning.
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4625015A (en) 1982-08-23 1986-11-25 Scripps Clinic & Research Foundation Broad spectrum influenza antisera
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JP2518607B2 (ja) 1985-08-29 1996-07-24 雪印乳業株式会社 インフルエンザａ型ウイルスｈａ抗原に対するモノクロ―ナル抗体およびその作成方法
EP0349579B1 (en) 1987-03-13 1992-01-08 Micro Vesicular Systems, Inc. Lipid vesicles formed of surfactants and steroids
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
EP0417191B1 (en) 1988-05-27 1993-03-10 Centocor, Inc. Formulation for antibody reagents
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
GB9320597D0 (en) 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JP2996864B2 (ja) 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
DE19643314A1 (de) 1996-10-21 1998-04-23 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen das Epitop YPYDVPDYA, Verfahren zu deren Herstellung und Verwendung
FR2817869B1 (fr) 2000-12-07 2005-01-14 Technopharm Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci
KR100980065B1 (ko) 2002-09-27 2010-09-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
KR101130181B1 (ko) 2003-02-27 2012-03-28 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 인플루엔자 바이러스 감염의 치료 및 검출에 유용한 핵산분자, 폴리펩티드, 항체 및 이를 포함하는 조성물
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8496930B2 (en) 2003-10-01 2013-07-30 Kyowa Hakko Kirin Co., Ltd Method of stabilizing antibody and stabilized solution-type antibody preparation
EP2261377B1 (en) 2003-11-04 2013-10-02 The Administrators Of The Tulane Educational Fund Method of preventing virus:cell fusion by inhibiting the function of the fusion initiation region in RNA viruses having class I membrane fusogenic envelope proteins
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
JP4980896B2 (ja) 2004-05-25 2012-07-18 メディミューン，エルエルシー インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体
CA2591992A1 (en) * 2004-12-22 2006-06-29 The Salk Institute For Biological Studies Compositions and methods for producing recombinant proteins
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
US7566454B2 (en) 2005-02-24 2009-07-28 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
CN101379397A (zh) * 2006-01-26 2009-03-04 Hx诊断公司 H5亚型禽流感病毒血凝素蛋白的单克隆抗体或其结合活性片段及其用途
US8222204B2 (en) 2006-05-03 2012-07-17 The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC Influenza inhibiting compositions and methods
EP2024393A2 (en) 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
US8163876B2 (en) 2006-06-16 2012-04-24 Dow Agrosciences Llc DNA sequences, vectors and proteins of avian influenza hemagglutinin
CA2660128A1 (en) 2006-08-14 2008-02-21 Massachusetts Institute Of Technology Glycan data mining system
US20090081193A1 (en) 2006-08-14 2009-03-26 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US20090269342A1 (en) 2006-08-14 2009-10-29 Massachusetts Institute Of Technology Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
MY170607A (en) 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2008033105A1 (en) 2006-09-13 2008-03-20 Dso National Laboratories Hemagglutinin antibody and uses thereof
JP4625485B2 (ja) 2006-09-29 2011-02-02 財団法人大阪産業振興機構 高病原性トリインフルエンザウイルスに対するモノクローナル抗体
US8030029B2 (en) 2007-01-23 2011-10-04 Academia Sinica Flu vaccines and methods of use thereof
EP2125886A2 (en) 2007-03-13 2009-12-02 Humabs LLC Antibodies against h5n1 strains of influenza a virus
CA2680237C (en) 2007-03-27 2018-11-06 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
CN101687921A (zh) 2007-05-11 2010-03-31 淡马锡生命科学研究院有限公司 可用于h5禽流感诊断和监视的h5亚型特异性结合蛋白
WO2008143954A2 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP2716656B1 (en) 2007-06-15 2016-10-12 Xiamen University Monoclonal antibodies binding to avian influenza virus subtype H5 haemagglutinin and uses thereof
WO2008156763A2 (en) 2007-06-15 2008-12-24 The Board Of Trustees Of The Leland Stanford Junior University Human neutralizing monoclonal antibodies to h5n1 influenza a virus
US8444986B2 (en) 2007-09-13 2013-05-21 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin from influenza virus H5-subtype and uses thereof
EP2947094B1 (en) 2007-09-13 2018-11-14 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
WO2009073330A2 (en) 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Novel vaccines against multiple subtypes of influenza virus
WO2009073163A1 (en) 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
WO2009079259A2 (en) 2007-12-06 2009-06-25 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US7981428B2 (en) 2008-01-23 2011-07-19 Academia Sinica Flu vaccines and methods of use thereof
US8574830B2 (en) 2008-02-05 2013-11-05 Temasek Life Sciences Laboratory Limited Binding protein and epitope-blocking ELISA for the universal detection of H5-subtype influenza viruses
US8669046B2 (en) 2008-03-12 2014-03-11 Xuguang (Sean) Li Reagents and methods for detecting influenza virus proteins
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
KR101625979B1 (ko) 2008-03-28 2016-05-31 국립대학법인 홋가이도 다이가쿠 항 ｈ5 아형 ａ형 인플루엔자 바이러스 헤마글루티닌 모노클로날 항체
AU2009228058A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
FI20080333A0 (fi) 2008-05-02 2008-05-02 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
SI2285408T1 (sl) 2008-06-05 2019-02-28 Ablynx N.V. Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni
BRPI0915487A2 (pt) 2008-07-11 2017-06-27 Medimmune Inc hemaglutina de nfluenza e variantes de neuraminidase
KR20110049802A (ko) 2008-07-25 2011-05-12 인스티튜트 포 리서치 인 바이오메드슨 중화 항-인플루엔자 ａ 바이러스 항체 및 이의 용도
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
US20100061995A1 (en) 2008-09-08 2010-03-11 Damian Michael Carragher Immunotherapy To Treat Or Prevent Viral Infection
GB0818356D0 (en) 2008-10-07 2008-11-12 Istituto Superiore Di Sanito Antibodies
WO2010040281A1 (zh) 2008-10-09 2010-04-15 厦门大学 H5亚型禽流感病毒血凝蛋白的人源化抗体及其用途
US9347043B2 (en) 2008-10-22 2016-05-24 Institute For Research In Biomedicine Methods for producing antibodies from plasma cells
SG172333A1 (en) 2008-12-24 2011-07-28 Temasek Life Sciences Lab Ltd Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof
EP2380976A4 (en) 2008-12-25 2012-11-07 Univ Osaka HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
US8894997B2 (en) 2009-04-30 2014-11-25 Vanderbilt University Monoclonal antibodies to influenza H1N1 virus uses thereof
US8470327B2 (en) 2009-05-11 2013-06-25 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof
WO2010132604A2 (en) 2009-05-13 2010-11-18 Sea Lane Biotechnologies, Llc Neutralizing molecules to influenza viruses
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
EP2448596B1 (en) 2009-07-02 2016-01-06 Massachusetts Institute of Technology Compositions and methods for diagnosing and/or treating influenza infection
EP2464383A4 (en) 2009-08-14 2013-02-13 Theraclone Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF FLU
CA2776144C (en) 2009-09-29 2020-10-27 Fraunhofer Usa, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
US9458226B2 (en) 2009-10-09 2016-10-04 Emory University Recombinant antibodies against H1N1 influenza
WO2011068143A1 (ja) 2009-12-03 2011-06-09 独立行政法人科学技術振興機構 Ｈ５亜型インフルエンザウイルスに対する抗体およびその利用
JP2013060367A (ja) 2010-01-15 2013-04-04 Osaka Univ 抗インフルエンザ抗体及びインフルエンザ検出用デバイス
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
AU2011210840B2 (en) 2010-01-27 2014-12-11 Massachusetts Institute Of Technology Engineered polypeptide agents for targeted broad spectrum influenza neutralization
WO2011093217A1 (ja) 2010-01-29 2011-08-04 富士レビオ株式会社 抗Pandemic (H1N1) 2009抗体及びそれを用いた免疫測定方法
WO2011096302A1 (ja) 2010-02-02 2011-08-11 国立大学法人名古屋大学 薬剤耐性インフルエンザウイルス特異的抗体及びその用途
JP2011160681A (ja) 2010-02-05 2011-08-25 Japan Science & Technology Agency Ａ型インフルエンザのヘマグルチニンに対する抗体およびその利用
JP5795340B2 (ja) 2010-03-08 2015-10-14 セルトリオン インクＣｅｌｌｔｒｉｏｎ，Ｉｎｃ． インフルエンザａ型ウイルスに対して中和活性を有するヒトｂ細胞由来のヒトモノクローナル抗体
EP2552485B1 (en) 2010-03-26 2017-03-08 Pomona Ricerca S.r.l. Full-length immunoglobulins of the igg isotype capable of recognizing a heterosubtype neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament
JP6050747B2 (ja) 2010-06-17 2016-12-21 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー インフルエンザ受動免疫化に有用な抗体
JP2013540701A (ja) 2010-08-12 2013-11-07 セラクローン サイエンシーズ， インコーポレイテッド 抗赤血球凝集素抗体組成物およびその使用方法
US8992929B2 (en) 2010-08-23 2015-03-31 Temasek Life Sciences Laboratory Limited Monoclonal antibody specific to major neutralizing epitope of influenza H5 hemagglutinin
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
JP2013541528A (ja) 2010-09-21 2013-11-14 マサチューセッツ インスティテュート オブ テクノロジー ヒト適応ｈａポリペプチド、ワクチン、およびインフルエンザの処置
US20130289246A1 (en) 2010-09-30 2013-10-31 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
SG189236A1 (en) 2010-10-04 2013-05-31 Massachusetts Inst Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
WO2012054745A1 (en) 2010-10-20 2012-04-26 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
WO2012072788A1 (en) 2010-12-02 2012-06-07 Mab-Factory Gmbh Vaccine against influenza h5n1 viruses, medicament and treatment of h5n1 viral infections
EP2663334A4 (en) 2011-01-10 2016-01-13 Univ Emory ANTIBODIES AGAINST INFLUENZA
US8961978B2 (en) 2011-07-14 2015-02-24 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
LT2734545T (lt) 2011-07-18 2019-05-10 Institute For Research In Biomedicine Antikūnai, neutralizuojantys influenza a virusą, ir jų panaudojimo būdai
EP2739312B1 (en) 2011-08-03 2017-10-04 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
GB201115214D0 (en) 2011-09-02 2011-10-19 Health Prot Agency Influenza virus antibody compositions
WO2013044840A1 (zh) 2011-09-30 2013-04-04 中国科学院上海巴斯德研究所 高致病性禽流感的中和分子及其制备方法
AU2012316930B2 (en) 2011-09-30 2016-06-09 Celltrion Inc. Binding molecule having influenza A virus-neutralizing activity produced from human B cell
CA2852474A1 (en) 2011-10-18 2013-04-25 Emory University Antibodies directed against influenza
KR20130059721A (ko) 2011-11-29 2013-06-07 (주)셀트리온 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자
SG11201402780UA (en) 2011-12-02 2014-10-30 Aimm Therapeutics Bv Influenza a virus specific antibodies
CN104302321A (zh) 2011-12-05 2015-01-21 特瑞利斯生物科学有限责任公司 可用于被动流感免疫的抗体
KR101749316B1 (ko) 2011-12-15 2017-06-21 (주) 에이프로젠 Ｈ１ｎ１―감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물
WO2013114885A1 (en) 2012-01-31 2013-08-08 Osaka University Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same
ES2664625T3 (es) 2012-03-08 2018-04-20 Janssen Vaccines & Prevention B.V. Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos
US9683030B2 (en) 2012-05-10 2017-06-20 Massachusetts Institute Of Technology Agents for influenza neutralization
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
WO2014124319A2 (en) 2013-02-07 2014-08-14 Massachusetts Institute Of Technology Human adaptation of h5 influenza
LT3052192T (lt) 2013-10-02 2020-12-10 Medimmune, Llc Neutralizuojantys antikūnai prieš gripą a ir jų naudojimas
RU2682049C2 (ru) 2014-01-27 2019-03-14 Дженентек, Инк. Лечение вируса гриппа а h7n9
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3280730B1 (en) 2015-04-08 2024-01-03 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2017104691A1 (ja) 2015-12-15 2017-06-22 塩野義製薬株式会社 キャップ依存的エンドヌクレアーゼ阻害剤及び抗インフルエンザ薬を組み合わせることを特徴とするインフルエンザ治療用医薬
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
JP2023506156A (ja) 2019-12-11 2023-02-15 ビステラ， インコーポレイテッド インフルエンザを処置または予防するための組成物および方法

Also Published As

Publication number Publication date
US10800835B2 (en) 2020-10-13
WO2013170139A1 (en) 2013-11-14
CN108948189A (zh) 2018-12-07
IL235585B (en) 2020-10-29
MX366180B (es) 2019-07-01
HK1208619A1 (en) 2016-03-11
MX2019007921A (es) 2019-09-10
CA2872308A1 (en) 2013-11-14
US20140148581A1 (en) 2014-05-29
ES2785306T3 (es) 2020-10-06
MX2014013668A (es) 2015-04-08
IL235585A0 (en) 2015-01-29
CN104602709B (zh) 2018-07-31
US20130302349A1 (en) 2013-11-14
AU2018200451B2 (en) 2019-01-03
JP6363066B2 (ja) 2018-07-25
US9096657B2 (en) 2015-08-04
CA2872308C (en) 2021-01-26
CN104602709A (zh) 2015-05-06
EP2846832B1 (en) 2020-01-22
JP2018015012A (ja) 2018-02-01
BR112014028109A2 (pt) 2017-06-27
KR20200142127A (ko) 2020-12-21
US12024552B2 (en) 2024-07-02
US20220204592A1 (en) 2022-06-30
AU2018200451A1 (en) 2018-02-08
KR20150008164A (ko) 2015-01-21
AU2013259371B2 (en) 2018-01-04
JP6800828B2 (ja) 2020-12-16
KR102366115B1 (ko) 2022-02-23
US20150037352A1 (en) 2015-02-05
AU2019202107A1 (en) 2019-05-02
KR102194936B1 (ko) 2020-12-28
SG11201407265RA (en) 2014-12-30
AU2013259371A1 (en) 2014-10-30
SG10201605669WA (en) 2016-08-30
US20190002536A1 (en) 2019-01-03
JP2015519052A (ja) 2015-07-09
US9969794B2 (en) 2018-05-15
EP2846832A1 (en) 2015-03-18
US8877200B2 (en) 2014-11-04
EP3689377A1 (en) 2020-08-05

Similar Documents

Publication Publication Date Title
CL2014003051A1 (es) Anticuerpo de unión a hemaglutinina (ha) de diversos virus de la influenza; ácido nucleico que lo codifica; vector; célula huésped; método de elaboración; método de detección de virus de la influenza; composición farmacéutica; vacuna; y kit.
FR23C1032I2 (fr) Protéines de liaison à bcma (cd269/tnfrsf17)
EP3551193A4 (en) NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
EP3365445A4 (en) METHOD OF GENOMEMBLING, HAPLOTYP PHASING AND TARGET INDEPENDENT NUCLEIC ACID DETECTION
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
BR112013020070A2 (pt) moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas
BR112014029274A2 (pt) anticorpo isolado, composição farmacêutica, uso do anticorpo, método para tratar infecção rábica, kit para tratar infecção rábica, kit para detectar vírus rábico, ácido nucleico isolado, e, célula hospedeira.
EP2928924A4 (en) HIV-1 ENV BINDING ANTIBODIES, FUSION PROTEINS AND METHODS OF USE
BR112016000303A2 (pt) partícula tipo viral que compreende antígeno pd-1 ou antígeno ligante pd-1, molécula de ácido nucleico isolada, vetor, composição farmacêutica, uso dos mesmos, e kit
DK4357457T3 (da) Sammensætning til spaltning af et mål-dna omfattende et guide-rna, der er specifikt for mål-dna'et og den cas-protein-kodende nukleinsyre eller cas-proteinet, samt anvendelse deraf
EP2663334A4 (en) ANTIBODIES AGAINST INFLUENZA
BR112014017518A8 (pt) anticorpo e ácido nucleico isolados, célula hospedeira, métodos, imunoconjugado, formulação farmacêutica e uso do anticorpo
EP2812348A4 (en) COMPREHENSIVELY OPTIMIZED, WIDE-REACTIVE ANTIGEN FOR H3N2, H2N2 AND B INFLUENZA VIRUSES
HUE038850T2 (hu) Eljárások és kompozíciók cél-DNS RNS-irányított módosításához és transzkripció RNS-irányított modulálásához
EP2817421A4 (en) Detection of nucleic acids
IL252446A0 (en) Inhibitors of hepatitis c virus
CO7010813A2 (es) Sistema de puente de concreto y métodos relacionados
BR112013011705A2 (pt) antígenos consensuais de próstata, molécula de ácido nucleico que os codificam e vacina e usos que os compreendem
EP2831094A4 (en) COMPREHENSIVELY OPTIMIZED, WIDE-REACTIVE ANTIGEN FOR H5N1 AND H1N1 INFLUENZA VIRUSES
DK3191489T3 (da) Pyrrolopyrimidiner til anvendelse ved influenzavirusinfektion
EA201590860A1 (ru) Варианты гемагглютинина и нейраминидазы вируса свиного гриппа
EP2672992A4 (en) FOR A HEPATITIS B-VIRUS CORE PROTEIN, CODING NUCLEIC ACID MOLECULE AND VACCINE WITH IT
CL2014002019A1 (es) Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
EP2915815A4 (en) NEW MODIFIED NUCLEIC ACID
EP2576581A4 (en) RECOMBINANT RNA VIRUSES AND USES THEREOF